AU2021279079A1 - Engineered coronavirus spike (s) protein and methods of use thereof - Google Patents

Engineered coronavirus spike (s) protein and methods of use thereof Download PDF

Info

Publication number
AU2021279079A1
AU2021279079A1 AU2021279079A AU2021279079A AU2021279079A1 AU 2021279079 A1 AU2021279079 A1 AU 2021279079A1 AU 2021279079 A AU2021279079 A AU 2021279079A AU 2021279079 A AU2021279079 A AU 2021279079A AU 2021279079 A1 AU2021279079 A1 AU 2021279079A1
Authority
AU
Australia
Prior art keywords
engineered
protein
substitution
engineered protein
positions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021279079A
Other languages
English (en)
Inventor
Patrick Byrne
Andrea CHASSE
Chia-Wei Chou
Ilya FINKELSTEIN
Jory GOLDSMITH
Christy HJORTH
Ching-Lin Hsieh
Mohammad JAVANMARDI
Nicole Johnson
Hung-Che KUO
Jennifer MAYNARD
Jason MCLELLAN
Jeffrey SCHAUB
Nianshuang WANG
Daniel WRAPP
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dartmouth College
University of Texas System
Original Assignee
Dartmouth College
University of Texas System
University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dartmouth College, University of Texas System, University of Texas at Austin filed Critical Dartmouth College
Publication of AU2021279079A1 publication Critical patent/AU2021279079A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2021279079A 2020-05-29 2021-05-28 Engineered coronavirus spike (s) protein and methods of use thereof Pending AU2021279079A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063032502P 2020-05-29 2020-05-29
US63/032,502 2020-05-29
PCT/US2021/034713 WO2021243122A2 (en) 2020-05-29 2021-05-28 Engineered coronavirus spike (s) protein and methods of use thereof

Publications (1)

Publication Number Publication Date
AU2021279079A1 true AU2021279079A1 (en) 2022-12-15

Family

ID=78722816

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021279079A Pending AU2021279079A1 (en) 2020-05-29 2021-05-28 Engineered coronavirus spike (s) protein and methods of use thereof

Country Status (10)

Country Link
EP (1) EP4157345A4 (https=)
JP (1) JP2023527556A (https=)
KR (1) KR20230018394A (https=)
CN (1) CN116802193A (https=)
AU (1) AU2021279079A1 (https=)
BR (1) BR112022023591A2 (https=)
CA (1) CA3180554A1 (https=)
IL (1) IL298131A (https=)
MX (1) MX2022015040A (https=)
WO (1) WO2021243122A2 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012323782B2 (en) 2011-10-12 2017-04-06 Vaxxas Pty Limited Delivery device
US12194089B2 (en) 2020-02-04 2025-01-14 CureVac SE Coronavirus vaccine
WO2021229270A1 (es) 2020-05-13 2021-11-18 Laboratorio Avi-Mex, S.A. De C.V. Vacuna recombinante contra covid-19 en vector viral
WO2021249011A1 (en) 2020-06-10 2021-12-16 Sichuan Clover Biopharmaceuticals, Inc. Hiv vaccine compositions, methods, and uses thereof
WO2021249116A1 (en) 2020-06-10 2021-12-16 Sichuan Clover Biopharmaceuticals, Inc. Coronavirus vaccine compositions, methods, and uses thereof
WO2022041760A1 (en) 2020-08-31 2022-03-03 Sichuan Clover Biopharmaceuticals, Inc. Methods and compositions for purification of trimeric fusion proteins
US11918643B2 (en) 2020-12-22 2024-03-05 CureVac SE RNA vaccine against SARS-CoV-2 variants
WO2023067193A2 (en) 2021-10-22 2023-04-27 BioNTech SE Compositions for administration of different doses of rna
US20250122546A1 (en) 2021-10-28 2025-04-17 BioNTech SE Rna constructs and uses thereof
AU2022398292A1 (en) 2021-11-29 2024-06-13 BioNTech SE Coronavirus vaccine
WO2023147091A1 (en) 2022-01-28 2023-08-03 BioNTech SE Coronavirus vaccine
WO2023196634A2 (en) * 2022-04-08 2023-10-12 Flagship Pioneering Innovations Vii, Llc Vaccines and related methods
WO2024002985A1 (en) 2022-06-26 2024-01-04 BioNTech SE Coronavirus vaccine
WO2024086575A1 (en) 2022-10-17 2024-04-25 BioNTech SE Combination vaccines against coronavirus infection, influenza infection, and/or rsv infection
EP4608442A1 (en) 2022-10-28 2025-09-03 GlaxoSmithKline Biologicals S.A. Nucleic acid based vaccine
EP4670167A1 (en) 2023-02-24 2025-12-31 BioNTech SE Systems and methods for modifying synthetic antigens to promote personalized immune responses
EP4669348A1 (en) 2023-02-24 2025-12-31 BioNTech SE IMMUNOGENEOUS COMPOSITIONS
WO2024243641A1 (en) * 2023-06-02 2024-12-05 Vaxxas Pty Limited Covid vaccine delivered by hd-map
WO2024249848A2 (en) * 2023-06-02 2024-12-05 The Scripps Research Institute Coronavirus s2 immunogens
WO2025106754A1 (en) 2023-11-15 2025-05-22 BioNTech SE Coronavirus vaccine
FR3155424A1 (fr) 2023-11-15 2025-05-23 BioNTech SE Compositions immunogènes contre le sars-cov-2
WO2025179238A2 (en) 2024-02-23 2025-08-28 BioNTech SE Coronavirus vaccine
WO2026047603A1 (en) 2024-08-28 2026-03-05 BioNTech SE Sars-cov-2 immunogenic compositions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2970398B1 (en) * 2013-03-13 2024-05-08 The United States of America, as Represented by The Secretary, Department of Health and Human Services Prefusion rsv f proteins and their use
US10538557B2 (en) * 2015-09-02 2020-01-21 Janssen Vaccines & Prevention B.V. Stabilized viral class I fusion proteins
US10960070B2 (en) * 2016-10-25 2021-03-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion coronavirus spike proteins and their use
US11890339B2 (en) * 2018-08-03 2024-02-06 The United States of Americam as represented by the Secretary, Department of Health and Human Services Nipah virus immunogens and their use
CN111088283B (zh) * 2020-03-20 2020-06-23 苏州奥特铭医药科技有限公司 mVSV病毒载体及其病毒载体疫苗、一种基于mVSV介导的新冠肺炎疫苗

Also Published As

Publication number Publication date
KR20230018394A (ko) 2023-02-07
JP2023527556A (ja) 2023-06-29
IL298131A (en) 2023-01-01
CN116802193A (zh) 2023-09-22
EP4157345A2 (en) 2023-04-05
CA3180554A1 (en) 2021-12-02
WO2021243122A3 (en) 2022-02-10
WO2021243122A2 (en) 2021-12-02
EP4157345A4 (en) 2024-09-11
US20230242594A1 (en) 2023-08-03
BR112022023591A2 (pt) 2022-12-27
MX2022015040A (es) 2023-02-27
WO2021243122A8 (en) 2022-01-06

Similar Documents

Publication Publication Date Title
AU2021279079A1 (en) Engineered coronavirus spike (s) protein and methods of use thereof
US11919927B2 (en) Prefusion-stabilized hMPV F proteins
US20240317810A1 (en) Prefusion-stabilized chimeric hmpv-rsv f proteins
WO2024050549A2 (en) Prefusion-stabilized cmv gb proteins
WO2022241229A1 (en) Stabilized s2 beta-coronavirus antigens
US12617820B2 (en) Engineered coronavirus spike (s) protein and methods of use thereof
US12616747B2 (en) Stabilized beta-coronavirus antigens
US20230277653A1 (en) Stabilized beta-coronavirus antigens
WO2025171082A1 (en) Prefusion-stabilized hsv2 gb proteins
WO2024151586A2 (en) Prefusion-stabilized human parainfluenza virus 3 f proteins
WO2025212898A1 (en) Pre-fusion stabilized cchfv gp38-gn-gc glycoprotein complex
BR122024021506A2 (pt) Moléculas de ácido nucleico de proteína engenheirada compreendendo um ectodomínio de proteína f de metapneumovírus (mpv), e composiçao farmacêutica
BR122025014411A2 (pt) Molécula de ácido nucleico e composição farmacêutica que compreende a mesma